

Technology Advisory Interests Register

Topic: Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]

Publication Date: Thursday 8 January 2026

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	TAC Committee Member	Direct- financial	Michael has participated in an advisory panel for Pfizer (possible comparator company) in an unrelated disease area: prostate cancer, and an advisory board for Accord (possible comparator company) in an unrelated disease area: small-cell lung cancer	14/03/2025	It was agreed that Michael's declaration would not prevent them from participating in discussions on this appraisal
Elizabeth Thurgar	TAC Committee Member	Direct- financial	Within the last 12 months worked with Bristol Myers Squibb Pharmaceuticals in an unrelated indication, myelodysplastic syndrome. She is currently working with Pfizer in an unrelated indication, non-small cell lung cancer	14/03/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Kate Ren	TAC Committee Member	Direct- financial	Kate is currently preparing a training course on indirect treatment comparison for MSD's HTA statistics team. This is not related to any specific treatment or disease area. She also provided statistical methodology consultancy service to	19/03/2025	It was agreed that Kate's declaration would not prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).		
Ricky Frazer	Clinical Expert	Direct- financial	Ricky has received fees from Merck Serono for an advisory board and educational events. He has also received sponsorship and advisory board fees from BMS, Eisai, Eusa, Ipsen, MSD, Novartis and Pfizer.	30/09/2024	It was agreed that Ricky's declaration would not prevent them from providing expert advice to the committee
Naveen Vasudev	Clinical Expert	Direct- financial	Naveen has attended Merck UK and global advisory boards. They have received advisory board fees from MSD and EUSA Pharma (now Recordati). They have received speaker honoraria from Ipsen, Eisai and Recordati. Their nominating organisation Action Kidney Cancer has received a grant from Merck Serono to fund their community support project.	14/10/2024	It was agreed that Naveen's declaration would not prevent them from providing expert advice to the committee
Hazel Jackson	Patient Expert	Professional	Hazel's employer and nominating organisation Kidney Cancer UK has received funding from Merck Serono, BMS, Ipsen, MSD and Pfizer for specific projects.	29/11/2024	It was agreed that Hazel's declaration would not prevent them from providing expert advice to the committee

